Clinical Trials Logo

Clinical Trial Summary

Polycythemia (PG) corresponds to an increase in erythrocyte parameters on a blood test. A distinction is usually made between primary and secondary PG. The most common primary PG is Vaquez's disease, a hematological cancer. In Vaquez disease, an increase in hematocrit has been reported to be associated with a logarithmic increase in blood viscosity. The main complications of primary PGs (especially in Vaquez disease) are thromboembolic complications. In contrast, thromboembolic complications are rarer in secondary PG. In Vaquez disease, a hematocrit ≤ 45% has been defined as the therapeutic goal for significantly reducing thromboembolic risk. However, this has not been established for secondary PGs. All in all, the definition of the 45% threshold is based solely on clinical studies with no obvious biological argument. What's more, simply lowering blood mass through cytoreduction alone does not appear to be sufficient to significantly reduce thromboembolic risk. To investigator knowledge, there are no studies prospectively evaluating blood viscosity, its determinants and coagulation in different types of polycythemia. Nor are there any data on the direct effect on blood viscosity of the various treatments usually offered.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06421025
Study type Observational
Source Hospices Civils de Lyon
Contact Mael HEIBLIG, MD,PhD
Phone 478862240
Email mael.heiblig@chu-lyon.fr
Status Not yet recruiting
Phase
Start date May 30, 2024
Completion date May 30, 2031

See also
  Status Clinical Trial Phase
Completed NCT03624335 - Influence of Umbilical Cord Clamping Time in the Newborn N/A